Literature DB >> 8573303

CD28 and apoptosis.

L H Boise1, P J Noel, C B Thompson.   

Abstract

Until recently, it was thought that signal transduction through CD28 and the related molecule CTLA4 prevented the induction of anergy in T cells activated through the TCR. This hypothesis has been suggested as an explanation for how soluble forms of CTLA4, which bind the CD28/CTLA4 ligands B7-1 and B7-2, can prevent graft rejection. Recent reports suggest that another function of CD28 costimulation is the regulation of T-cell survival. CD28 not only enhances IL-2 production, which can act as an extrinsic regulator of cell survival, but also augments the expression of the intrinsic survival factor Bcl-xL. In contrast, CTLA4-mediated signal transduction has been reported to induce cell death in previously activated T cells. These data suggest that B7-1/B7-2 signaling not only controls cell proliferation and T-helper cell subset selection, but also T-cell survival.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8573303     DOI: 10.1016/0952-7915(95)80067-0

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  17 in total

1.  Lack of costimulation by both sphingomyelinase and C2 ceramide in resting human T cells.

Authors:  D O'Byrne; D Sansom
Journal:  Immunology       Date:  2000-06       Impact factor: 7.397

2.  Toll-like receptor ligands directly promote activated CD4+ T cell survival.

Authors:  Andrew E Gelman; Jidong Zhang; Yongwon Choi; Laurence A Turka
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

Review 3.  Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

4.  Down-regulation of Th2 responses by Brucella abortus, a strong Th1 stimulus, correlates with alterations in the B7.2-CD28 pathway.

Authors:  I Agranovich; D E Scott; D Terle; K Lee; B Golding
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

5.  Cutting edge: A double-mutant knockin of the CD28 YMNM and PYAP motifs reveals a critical role for the YMNM motif in regulation of T cell proliferation and Bcl-xL expression.

Authors:  Jonathan S Boomer; Christine M Deppong; Dulari D Shah; Traci L Bricker; Jonathan M Green
Journal:  J Immunol       Date:  2014-03-17       Impact factor: 5.422

6.  Vaccines with enhanced costimulation maintain high avidity memory CTL.

Authors:  Sixun Yang; James W Hodge; Douglas W Grosenbach; Jeffrey Schlom
Journal:  J Immunol       Date:  2005-09-15       Impact factor: 5.422

7.  PD-1 gene promoter polymorphisms correlate with a poor prognosis in non-small cell lung cancer.

Authors:  Hidefumi Sasaki; Tsutomu Tatemaysu; Katsuhiro Okuda; Satoru Moriyama; Motoki Yano; Yoshitaka Fujii
Journal:  Mol Clin Oncol       Date:  2014-07-24

8.  Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma.

Authors:  Howard L Kaufman; Gail Deraffele; Josephine Mitcham; Dorota Moroziewicz; Seth M Cohen; Karl S Hurst-Wicker; Ken Cheung; David S Lee; Joseph Divito; Magalese Voulo; Julie Donovan; Kate Dolan; Kelledy Manson; Dennis Panicali; Ena Wang; Heidi Hörig; Francesco M Marincola
Journal:  J Clin Invest       Date:  2005-06-02       Impact factor: 14.808

Review 9.  Targeting the B7 family of co-stimulatory molecules: successes and challenges.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  BioDrugs       Date:  2013-02       Impact factor: 5.807

10.  CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes.

Authors:  Imke Tiede; Gerhard Fritz; Susanne Strand; Daniela Poppe; Radovan Dvorsky; Dennis Strand; Hans Anton Lehr; Stefan Wirtz; Christoph Becker; Raja Atreya; Jonas Mudter; Kai Hildner; Brigitte Bartsch; Martin Holtmann; Richard Blumberg; Henning Walczak; Heiko Iven; Peter R Galle; Mohammad Reza Ahmadian; Markus F Neurath
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.